VBI Vaccines, Inc. (VBIV)
| Market Cap | 780.62M |
| Revenue (ttm) | 1.47M |
| Net Income (ttm) | -41.74M |
| Shares Out | 234.71M |
| EPS (ttm) | -0.21 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $3.23 |
| Previous Close | $3.22 |
| Change ($) | 0.01 |
| Change (%) | 0.16% |
| Day's Open | 3.39 |
| Day's Range | 3.22 - 3.88 |
| Day's Volume | 25,723,374 |
| 52-Week Range | 0.73 - 6.17 |
Esperion Therapeutics (NASDAQ: ESPR) shares are trading lower after Bank of America Securities downgraded the stock from Buy to Neutral and announced a price target of $35 per share. Esprit Ho...
The company reported good news from a study of its hepatitis B vaccine.
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncol...
With risk-return not in your favor, steer clear of these 8 penny stocks, all of which could see big declines as the new year unfolds. Chesapeake Energy (OTCMKTS:CHKAQ) Genius Brands (NASDAQ:GN...
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncol...
Investors need to pay close attention to VBI Vaccines (VBIV) stock based on the movements in the options market lately.
CAMBRIDGE, Mass. & MORRISVILLE, N.C.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company developing next-generation infectious disease and immuno-on...
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncol...
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncol...
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncol...
VBI Vaccines' (VBIV) early-stage hepatitis B virus immunotherapeutic candidate, VBI-2601, achieves promising immune response in patients on interim analysis.
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) ("VBI") a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-onco...
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncol...
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncol...
Investors need to pay close attention to VBI Vaccines (VBIV) stock based on the movements in the options market lately.
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncol...
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncol...
"Buy low, sell high" is easy when stocks are cheap. The hard part is finding inexpensive healthcare stocks that are more than just speculative trades.
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncol...
Here's why investors should stay away from some of the riskiest coronavirus stocks on the market.
Neither biotech is in the front of the pack in developing a COVID-19 vaccine.
It wasn't just toilet paper that was in demand when Covid-19 hit us as short-term stocks flew through the roof. But with a second wave upon us, this narrative looks very compelling.
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncol...
In the latest trading session, VBI Vaccines, Inc. (VBIV) closed at $2.95, marking a +0.68% move from the previous day.
In the race for a vaccine, a pause in progress sets you back.
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncol...
In the latest trading session, VBI Vaccines, Inc. (VBIV) closed at $2.98, marking a +0.68% move from the previous day.
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncol...
VBI Vaccines, Inc. (VBIV) closed the most recent trading day at $3.76, making no change from the previous trading session.
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc.
The biotech will present additional data for one of its pipeline candidates later this week.
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc.
VBI Vaccines, Inc. (VBIV) closed at $3.12 in the latest trading session, marking a +0.65% move from the prior day.
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc.
Investors who are looking for promising coronavirus vaccine stocks should keep an eye out for this emerging biotech.
VBI Vaccines (VBIV) selects two coronavirus vaccine candidates for clinical-stage development based on encouraging pre-clinical data.
Pre-clinical results indicate that both are effective in only single doses.
Shares of VBI Vaccines Inc (NASDAQ: VBIV) are moving strongly to the upside Thursday.
Investors are fired up about an analyst's enthusiastic upgrade of the biotech stock.
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc.
The potential rewards with this biotech stock are high, but so are the risks.
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc.
If you're hoping this biotech will win big with its coronavirus vaccine candidate, you may be looking in the wrong place.
MISSISSAUGA, Ontario--(BUSINESS WIRE)--Therapure Biomanufacturing, a division of Therapure Biopharma Inc., announced today the signing of an agreement with VBI Vaccines Inc.
OTTAWA, Ontario & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--Variation Biotechnologies Inc.
VBI Vaccines, Inc. (VBIV) delivered earnings and revenue surprises of 20.00% and -78.48%, respectively, for the quarter ended June 2020.
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc.
One biotech keeps making headlines, the other's much quieter. But both have been big gainers, and both have strong potential opportunities.
VBI Vaccine (VBIV) will provide financial updates when it releases second-quarter 2020 results.
About VBIV
VBI Vaccines, a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology in Israel, the United States, and internationally. The company offers Sci-B-Vac, a prophylactic hepatitis B vaccine for adults, children, and newborns. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for a functional cure of chronic hepatitis B. The company's enveloped virus-like particle (eVLP) platform technology allows for the development of eVLP vaccines that mimic the ... [Read more...]
| Industry Biotechnology | |
| CEO Jeffrey R. Baxter F.C.M.A., FCMA | Employees 123 |
| Stock Exchange NASDAQ | Ticker Symbol VBIV |
Financial Performance
In 2019, VBI Vaccines's revenue was $2.22 million, a decrease of -33.80% compared to the previous year's $3.36 million. Losses were -$54.81 million, -13.82% less than in 2018.
Analyst Forecasts
According to 4 analysts, the average rating for VBI Vaccines stock is "Strong Buy." The 12-month stock price forecast is 6.50, which is an increase of 101.55% from the latest price.